AstraZeneca: Fasenra gets orphan status for chronic disease
(CercleFinance.com) - AstraZeneca said that its asthma drug Fasenra has received an orphan drug designation from US health regulators for the treatment of eosinophilic granulomatosis with polyangiitis, a rare, chronic autoimmune disease.
Eosinophilic granulomatosis with polyangiitis - that is caused by the inflammation of small blood vessels - can cause damage to multiple organs and tissues.
As a monoclonal antibody, Fasenra attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Eosinophilic granulomatosis with polyangiitis - that is caused by the inflammation of small blood vessels - can cause damage to multiple organs and tissues.
As a monoclonal antibody, Fasenra attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death).
Copyright (c) 2018 CercleFinance.com. All rights reserved.